Contrast Media

Contrast media, also called contrast agents, are used to enhance the blood and perfusion in tissues. This includes iodine based contrast for on computed tomography (CT), gadolinium based agents for MRI and lipid bubble contrast agents used in ultrasound.

GE Healthcare has received U.S. FDA approval of its macrocyclic gadolinium-based MRI contrast agent, Clariscan (gadoterate meglumine), in pre-filled syringes. #RSNA20
News | Contrast Media | November 26, 2020
GE Healthcare Announces U.S. FDA approval of macrocyclic MRI Contrast Agent Clariscan in Pre-Filled Syringes
November 26, 2020 — GE Healthcare has received U.S. FDA approval of its macrocyclic gadolinium-based MRI contrast agent...
read more
Bracco Diagnostics Inc. announced it will be showcasing its full portfolio of diagnostic imaging solutions in an immersive digital experience at the first all-virtual Radiological Society of North America (RSNA) annual meeting being held November 29 through December 5.
News | Contrast Media Injectors | November 17, 2020
Bracco Showcases Immersive Digital Experience at RSNA20
November 17, 2020 — Bracco Diagnostics Inc. announced it will be showcasing its full portfolio of diagnostic imaging...
read more
Guerbet announced that it will highlight UNIK, a tailored solution for diagnostic imaging, at the 2020 annual meeting of the Radiological Society of North America (RSNA).
News | Contrast Media | November 17, 2020
Guerbet to Showcase its UNIK Solution at RSNA 2020
November 17, 2020 — Guerbet announced that it will highlight UNIK, a tailored solution for diagnostic imaging, at the...
read more
This study found cardiac MRI gadolinium-based contrast agents are safe for patient use. Overall, there were only 556 acute adverse effects in 145,855 contrast-enhanced MRIs, with only 47 being classified as severe. 

This study found cardiac MRI gadolinium-based contrast agents are safe for patient use. Overall, there were only 556 acute adverse effects in 145,855 contrast-enhanced MRIs, with only 47 being classified as severe. 

Feature | Magnetic Resonance Imaging (MRI) | October 29, 2020
Cardiac MRI Contrast Agents Carry Low Risk of Adverse Events
October 29, 2020 — Contrast agents used to improve views of the heart on magnetic resonance imaging (MRI) carry a very...
read more
When new installations are ordered, the DAS team at Bracco matches a specialist with the installation based on specialty, learning style and industry awareness. This approach was helpful at Beaufort Memorial Hospital in Beaufort, S.C., which just recently transitioned to the Bracco EmpowerCTA+ Injector System.
Sponsored Content | Blog | Contrast Media | October 20, 2020
BLOG: Training and Vendor Support Key to Successful Device Upgrade
Transitioning to a new device vendor can provide improvements to outdated technology and workflow. It also requires a...
read more
the Contrast Media Injectors Market is estimated to be USD 1.3 billion in 2020 and  projected to reach $1.9B by 2025, at a CAGR of 7.4% between 2020 and 2025

Getty Images

News | Contrast Media Injectors | September 02, 2020
Contrast Media Injectors Market Projected at $1.9 billion by 2025
September 2, 2020 — According to the new market research report "Contrast Media Injectors Market By Product (Injector...
read more
The radiology department uses Bracco’s Empower CTA injector system and has a been a Bracco customer for more than 15 years.
Sponsored Content | Blog | Contrast Media Injectors | August 20, 2020
BLOG: Reliability and Customer Service Key to Injector Uptime and CT Department Workflow
In a busy hospital imaging department, maintaining high device uptime levels is critical. If an injector malfunctions...
read more
Subtle's AI improves MRI safety exams by reducing gadolinium dose
News | Artificial Intelligence | August 17, 2020
Subtle Medical Awarded Phase II Funding of $1.6 Million SBIR Grant for Safer MRI Exams
August 17, 2020 — Subtle Medical is approved for Phase II of its NIH SBIR grant to develop an innovative artificial...
read more
The first and only FDA-approved gadolinium-based contrast agent for multi-patient dosing with an FDA-cleared Transfer Spike in the MR suite
News | Contrast Media | August 14, 2020
FDA Approves Gadavist (gadobutrol) Imaging Bulk Package
August 14, 2020 — The U.S. Food and Drug Administration (FDA) announced the approval of the Gadavist (gadobutrol) ...
read more
The global contrast media market is projected to grow at a CAGR of 4.23% to reach US$7,113.91 million by 2025 from US$5,548.19 million in 2019, according to a new report from ResearchandMarkets.com
News | Contrast Media | July 22, 2020
Global Contrast Media Market Report 2020-2025: $7.1 Billion Industry Assessment
July 22, 2020 — The global contrast media market is projected to grow at a CAGR of 4.23% to reach US$7,113.91 million...
read more
Guerbet shows its commitment to healthcare professionals with two ranges of consumables selected for their injection solutions
News | Contrast Media Injectors | June 29, 2020
Guerbet Segments Consumables in Two Essential and Excellence Ranges
June 29, 2020 — Guerbet has launched a new "consumables.guerbet.com" website presenting its Essential and Excellence...
read more
The Global Contrast Injectors Market will grow by $613.47M during 2020-2024, according to Technavio
News | Contrast Media Injectors | June 17, 2020
Contrast Injectors Market Growth and Trends
June 17, 2020 — Technavio has been monitoring the contrast injectors market and it is poised to grow by $613.47M during...
read more
The FDA has approved Lilly’s TAUVID (flortaucipir F 18 injection), a radioactive diagnostic agent, for PET imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease

Getty Images

News | Contrast Media | June 01, 2020
FDA Approves TAUVID for Use in Patients Being Evaluated for Alzheimer’s Disease
June 1, 2020 — TAUVID, a radioactive diagnostic agent, has been approved by the FDA for positron emission tomography (...
read more
Researchers from Tokyo Metropolitan University have surveyed the amount of gadolinium found in river water in Tokyo. Gadolinium is contained in contrast agents given to patients undergoing medical magnetic resonance imaging (MRI) scans, and it has been shown in labs to become toxic when exposed to ultraviolet rays. The researchers found significantly elevated levels, particularly near water treatment plants, highlighting the need for new public policy and removal technologies as MRI become even more commonp

Samples were taken along rivers around Tokyo. Measurements of rare earth element quantities indicate a clearly elevated amount of gadolinium compared to that in natural shale. Graphics courtesy of Tokyo Metropolitan University

News | Magnetic Resonance Imaging (MRI) | May 26, 2020
MRI's Environmental Impact
May 26, 2020 — Researchers from Tokyo Metropolitan University have surveyed the amount of gadolinium found in river...
read more
Sponsored Content | Videos | Contrast Media Injectors | May 22, 2020
itnTV “Conversations”: Radiology Trends with Bayer’s Dennis Durmis
At this year’s RSNA ITN sat down with Dennis Durmis, Senior Vice President, Bayer Radiology to discuss Radiology trends...
read more
Gadolinium-based contrast agents

UT Dallas faculty members who collaborated with Dr. Jeremiah Gassensmith (center, back), associate professor of chemistry and biochemistry, include Dr. Lloyd Lumata (left, back), assistant professor of physics, and Dr. Steven Nielsen, associate professor of chemistry. Chemistry graduate students in Gassensmith’s lab include (from left, front) Oliva Brohlin, Arezoo Shahrivarkevishahi and Laurel Hagge.

News | Contrast Media | February 06, 2020
Researchers Brighten Path for Creating New Type of MRI Contrast Agent
February 6, 2020 — University of Texas at Dallas researchers are breathing new life into an old MRI contrast agent by...
read more
This image is of an 80 kg woman with a newly diagnosed IDH-wildtype glioblastoma

This image is of an 80 kg woman with a newly diagnosed IDH-wildtype glioblastoma. The quarter dose image on the left was obtained after the administration of 4 ml of MultiHance. Subsequently, an additional 12 ml of MultiHance was administered and the cumulative full dose image in the center was obtained. The image on the right was rendered following artificial intelligence processing of the 4 ml image using eGad genetic algorithms. This image has the quality of triple dose gadolinium even though only one quarter dose gadolinium was given.

Feature | Contrast Media Injectors | January 30, 2020 | By Matthew Kuhn, M.D., FACR
Artificial Intelligence Processes Provide Solutions to Gadolinium Retention Concerns
Gadolinium-based contrast agents (GBCAs) are widely used in medical imaging to provide essential diagnostic information...
read more

Image courtesy of Guerbet

Feature | Contrast Media Injectors | January 30, 2020 | By Melinda Taschetta-Millane
Contrast Media Injectors Market Outlook
Contrast media injector technology has seen several recent advances, such as cutting costs by reducing contrast waste...
read more
Gadolinium based contrast dye in brain MRI

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | January 17, 2020
Voluntary Dismissal of Chuck Norris Gadolinium Case Involving Bracco
January 17, 2020 — Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., one of the world’s leading...
read more
Results were presented at RSNA19 for the comparison of ProHance (Gadoteridol) Injection, 279.3 mg/mL and Gadavist (gadobutrol) Injection in MRI of the brain (the TRUTH study)
News | Contrast Media | December 10, 2019
AI Software Confirms the Results of a Large Scale Comparison of Gadoteridol and Gadavist Injection
December 10, 2019 — Bracco Diagnostics Inc., the U.S subsidiary of Bracco Imaging S.p.A., a leading global company in...
read more
© Copyright Wainscot Media. All Rights Reserved.